Avista Capital Partners has announced it has signed a definitive agreement to invest in eMolecules.
eMolecules, based in San Diego, is provider of high-value, hard-to-find chemicals and bioreagents used in early-stage drug discovery research. Founded in 2005, the company connects pharmaceutical and biotechnology researchers with reagents not offered by the usual commodity suppliers.
Avista Capital Partners, based in New York, makes control buyout investments in middle market healthcare companies. Founded in 2005, the firm focuses on the following healthcare subsectors: pharmaceuticals, medical devices, outsourced pharmaceutical services, distribution and consumer-driven healthcare.
Terms of the acquisition were not disclosed.